- Home
- CLGN vs NCNA Comparison
CLGN vs NCNA Comparison
Compare CLGN & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLGN
- NCNA
- Stock Information
- Founded
- CLGN 2004
- NCNA 1997
- Country
- CLGN Israel
- NCNA United Kingdom
- Employees
- CLGN N/A
- NCNA N/A
- Industry
- CLGN Industrial Specialties
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- CLGN Health Care
- NCNA Health Care
- Exchange
- CLGN Nasdaq
- NCNA Nasdaq
- Market Cap
- CLGN 19.1M
- NCNA 15.4M
- IPO Year
- CLGN N/A
- NCNA 2017
- Fundamental
- Price
- CLGN $2.63
- NCNA $4.15
- Analyst Decision
- CLGN Strong Buy
- NCNA Buy
- Analyst Count
- CLGN 2
- NCNA 2
- Target Price
- CLGN $11.50
- NCNA $5,000.00
- AVG Volume (30 Days)
- CLGN 45.8K
- NCNA 1.0M
- Earning Date
- CLGN 08-20-2025
- NCNA 08-26-2025
- Dividend Yield
- CLGN N/A
- NCNA N/A
- EPS Growth
- CLGN N/A
- NCNA N/A
- EPS
- CLGN N/A
- NCNA N/A
- Revenue
- CLGN $2,472,000.00
- NCNA N/A
- Revenue This Year
- CLGN $1,999.42
- NCNA N/A
- Revenue Next Year
- CLGN $69.81
- NCNA N/A
- P/E Ratio
- CLGN N/A
- NCNA N/A
- Revenue Growth
- CLGN N/A
- NCNA N/A
- 52 Week Low
- CLGN $1.31
- NCNA $4.12
- 52 Week High
- CLGN $5.45
- NCNA $2,158.00
- Technical
- Relative Strength Index (RSI)
- CLGN 60.49
- NCNA 30.77
- Support Level
- CLGN $2.59
- NCNA $4.12
- Resistance Level
- CLGN $3.23
- NCNA $5.70
- Average True Range (ATR)
- CLGN 0.29
- NCNA 1.18
- MACD
- CLGN 0.03
- NCNA -0.04
- Stochastic Oscillator
- CLGN 55.86
- NCNA 0.36
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.